Drug Trial Radar · NCT01785186
Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design
Last checked: Nov 19, 2026Latest source record: Sep 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
365
Actual
Start
Apr 2013
Primary completion
Sep 2014
Study completion Mar 2015
Sponsor
- Lead sponsor
- Michael HoelscherAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sequella, Inc.; European and Developing Countries Clinical Trials Partnership (EDCTP); German Federal Ministry of Education and Research; Medical Research Council; Radboud University Medical Center
- First posted
- Feb 7, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multiple-arm, multiple-stage (MAMS), phase 2, open label, randomized, controlled clinical trial that will compare the efficacy and safety of four experimental four drug regimens with a standard control regimen in patients with smear positive, pulmonary tuberculosis (TB). Patients will be randomly allocated to the control or one of the four experimental regimens in the ratio 2:1:1:1:1. Experimental regimens will be given for 12 weeks. Thereafter, participants in the experimental arms will receive continuation phase treatment for 14 weeks containing standard-dose rifampicin and isoniazid. All participants will receive 25 mg of vitamin B6 (pyridoxine) with every dose of INH to prevent INH-related neuropathy. Interim analyses will be conducted during the trial for efficacy, with the aim of identifying experimental arms that perform below a pre-specified efficacy threshold; these arms will then be stopped from further recruitment. Following the first scheduled interim analysis on March 3rd, the Trial Steering Committee (TSC) followed a recommendation of the independent data monitoring committee (IDMC) and has stopped the enrolment into two of the arms in the MAMS-TB trial: HRZQ and HR20ZQ, based on these arms not meeting the pre-specified gain in efficacy over control. Importantly, there was no safety concern that prompted stopping recruitment to these arms. They recommended that recruitment to arm 2 (HRZQ) and 3 (HR20ZQ) be terminated as there was insufficient evidence that these regimens could shorten treatment. Importantly, there was no evidence that either arm was inferior to standard treatment (the control arm) with regards to efficacy. There was, however, sufficient evidence that the other intervention arms HR35ZE and HR20ZM could shorten treatment to continue enrolling patients.
Conditions
- Tuberculosis, Pulmonary
Interventions
SQ109Drug
SQ109 300 mg
RifampicinDrug
Rifampicin 10 to 35 mg/kg
MoxifloxacinDrug
Moxifloxacin 400mg
isoniazidDrug
isoniazid 75 mg
pyrazinamideDrug
pyrazinamide 400 mg
ethambutolDrug
ethambutol 275 mg
pyridoxineDietary supplement
pyridoxine 25 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sputum Culture Conversion (2 Negative Cultures) Using Liquid MediaTime frame: 0 - 12 weeks
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
TASK Applied Science
Bellville, South Africa
University of Cape Town, Centre for Tuberculosis Research Innovation
Cape Town, South Africa
Wits Health Consortium
Johannesburg, South Africa
The Aurum Institute for Health Research
Johannesburg, South Africa
Ifakara Health Institute
Bagamoyo, Tanzania
NIMR - Mbeya Medical Research Programme
Mbeya, Tanzania
Kilimanjaro Christian Medical Centre (KCMC) / Kilimanjaro Clinical Research Institute (KCRI) (with affiliated field sites such as Kibong'oto National Tuberculosis Hospital Same, Mererani, Chekereni and Mawenzi Regional Hospital)
Moshi, Tanzania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.